Seracare心肌磷脂IgM（Cardiolipin IgM）
| 型 號： | 美國 |
| 報 價： |  |
美國SeracareSeracare心肌磷脂IgM（Cardiolipin IgM） 陽性質(zhì)控品對照品 需要了解更多Seracare產(chǎn)品可以咨詢我們，本產(chǎn)品由廣州健侖生物科技有限公司提供
- 產(chǎn)品描述
美國Seracare心肌磷脂IgM（Cardiolipin IgM）
廣州健侖生物科技有限公司
廣州健侖長期供應(yīng)各種生物原料，主要代理品牌：美國Seracare、西班牙Certest、美國Fuller等等。
主要產(chǎn)品包括各種標(biāo)準(zhǔn)品、陽性對照品、單克隆抗原抗體。
其中常見的有：弓形蟲病、西尼羅河病毒、類風(fēng)濕因子、瘧疾、麻疹、萊姆病、百日咳桿菌、大腸桿菌、鼠傷寒沙門氏菌、李斯特菌等陽性對照品。
美國Seracare心肌磷脂IgM（Cardiolipin IgM）
我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
歡迎咨詢
歡迎咨詢2042552662
【Seracare產(chǎn)品介紹】
編號 | 英文名稱 | 中文名稱 |
JL-FA-01 | Amebiasis (AME) | 阿米巴病 |
JL-FA-02 | Allergens, Rast scores | 過敏原，放射性過敏原吸收實驗。指對特定的人群引起免疫反應(yīng)或者過敏反應(yīng)的食品中的蛋白質(zhì) |
JL-FA-03 | Allergens, Rast scores negative | 過敏原，放射性過敏原吸收實驗陰性 |
JL-FA-04 | Anti-cyclic citrullinated peptide Antibody (CCP) Arthritis | 抗環(huán)瓜氨酸肽抗體 |
JL-FA-05 | ASCA Saccharomyces Cerevi | 人抗釀酒酵母抗體（ASCA） |
JL-FA-06 | Aspergillis | 麴菌病 |
JL-FA-07 | Beta 2 Glycoprotein | β2糖蛋白 |
JL-FA-08 | Beta 2 Glycoprotein IgM | β2糖蛋白 IGM |
JL-FA-09 | Bordela Pertussis | 百日咳桿菌 |
JL-FA-10 | Bordela Pertussis IgM | 百日咳桿菌 IGM |
JL-FA-11 | C-ANCA | C-抗中性粒細(xì)胞胞漿抗體（ANCA) |
JL-FA-12 | Cardiolipin | 心肌磷脂 |
JL-FA-13 | Cardiolipin IgA | 心肌磷脂 IGA |
JL-FA-14 | Cardiolipin IgG | 心肌磷脂 IGG |
JL-FA-15 | Cardiolipin IgM | 心肌磷脂 IGM |
JL-FA-16 | Cerebral Spinal Fluid | 腦脊髓液 |
JL-FA-17 | Chagas | 恰加斯病/南美錐蟲 |
JL-FA-18 | Chlamydia | 衣原體 |
JL-FA-19 | Chlamydia IgA | 衣原體IGA |
JL-FA-20 | Chlamydia IgG | 衣原體IGG |
JL-FA-21 | Chlamydia IgM | 衣原體IGM |
JL-FA-22 | Chlamydia Neg | 衣原體陰性 |
JL-FA-23 | Clotting Factor C3 | 凝固因子C3 |
JL-FA-24 | Clotting Factor C4 | 凝固因子C4 |
JL-FA-25 | Coccidiodes | 球孢菌 |
JL-FA-26 | Cytomegalovirus (CMV) Neg | 巨細(xì)胞病毒抗體陰性 |
JL-FA-27 | CMV IgG | 巨細(xì)胞病毒 IGG陽性 |
JL-FA-28 | CMV IgM VCA | 巨細(xì)胞病毒 IGM 陽性 |
JL-FA-29 | C-Reactive Protein (CRP) | C-反應(yīng)蛋白質(zhì) |
JL-FA-30 | Dengue Fever | 登革熱 |
JL-FA-31 | Dengue Fever IgM | 登革熱 IGM |
JL-FA-32 | DS (Double Stranded) DNA | 雙鏈脫氧核糖核酸 |
JL-FA-33 | EBNA (Epstein-Barr nuclear antigen) IgG | EB病毒核抗原 IGG |
JL-FA-34 | EBNA (Epstein-Barr nuclear antigen) IgM | EB病毒核抗原 IGM |
JL-FA-35 | Epstein Barr Virus (EBV) Negative Plasma | EB病毒陰性血漿 |
JL-FA-36 | Epstein Barr Virus (EBV) EA IgM | EB病毒早期抗原 IGM |
JL-FA-37 | Epstein Barr Virus (EBV) VCA IgM | EB病毒殼蛋白 IGM |
JL-FA-38 | Epstein Barr Virus (EBV) EA IgG | EB病毒早期抗原 IGG |
JL-FA-39 | EMA (Endomysial Antibodies) | 肌內(nèi)膜 |
JL-FA-40 | Gliadin | 麩蛋白,麥醇溶蛋白,麥膠蛋白 |
JL-FA-41 | Gliadin IgG | 麥醇溶蛋白 IGG |
JL-FA-42 | Gliadin IgA | 麥醇溶蛋白 IGA |
JL-FA-43 | Glomerular Basement Membrane (GBMA) | 腎小球基底膜病 |
JL-FA-44 | Helicobacter pylori IgA | 幽門螺旋桿菌IGA |
JL-FA-45 | Helicobacter pylori IgG | 幽門螺旋桿菌IGG |
JL-FA-46 | Helicobacter pylori IgM | 幽門螺旋桿菌IGM |
JL-FA-47 | Helicobacter pylori Negative | 幽門螺旋桿菌陰性 |
JL-FA-48 | Helicobacter pylori Positive Plasma | 幽門螺旋桿菌陰性血漿 |
JL-FA-49 | Hepatitis A Virus (HAV) Pos. Plasma | 甲型肝炎病毒陽性血漿 |
JL-FA-50 | Hepatitis A Virus (HAV) IgM | 甲型肝炎病毒IGM |
JL-FA-51 | Hepatitis B Core (HBc) IgG | 乙型肝炎病毒核心 IGG |
JL-FA-52 | Hepatitis B Core (HBc) IgM | 乙型肝炎病毒核心 IGM |
JL-FA-53 | Anti Hbe (Antibody to HBV antigen) | 乙肝抗體 |
JL-FA-54 | Hepatitis Delta Virus | 丁型肝炎病毒 |
JL-FA-55 | HBeAg (HBV e antigen) | 乙肝 E抗原 |
JL-FA-56 | anti-HBs (HBV surface antibody) | 乙肝表面抗體 |
JL-FA-57 | Hepatitis B (HBsAg) "Chronic" | 乙型肝炎（乙肝表面抗原）“慢性病 |
JL-FA-58 | HBsAg (HBV surface antigen) Serum | 乙肝表面抗原血清 |
JL-FA-59 | HBsAg (AD) | 乙肝表面抗原（AD） |
JL-FA-60 | HBsAg (AY) | 乙肝表面抗原（AY） |
JL-FA-61 | HBV Positive Plasma | 乙肝陽性血漿 |
JL-FA-62 | HBV DNA Plasma | 乙肝DNA血漿 |
JL-FA-63 | HBV DNA Serum | 乙肝DNA血清 |
JL-FA-64 | HBV DNA type A | A型 乙肝DNA |
JL-FA-65 | HBV DNA type B | B型 乙肝DNA |
JL-FA-66 | HBV DNA type C | C型 乙肝DNA |
JL-FA-67 | HBV DNA type D | D型 乙肝DNA |
JL-FA-68 | HBV DNA type E | E型 乙肝DNA |
JL-FA-69 | HBV DNA type F | F型 乙肝DNA |
JL-FA-70 | HBV Antibody HCV Antibody Plasma CO-INFECTED | 乙肝和丙肝聯(lián)合感染血漿 |
JL-FA-71 | HCV (Hepatitis C Virus) Antibody | 丙型肝炎抗體 |
JL-FA-72 | HCV Core Antigen Positive | 丙肝核心抗原 陽性 |
JL-FA-73 | HCV RNA PLASMA Genotype 1 | 基因1型丙肝RNA 血漿 |
JL-FA-74 | HCV RNA PLASMA Genotype 2 | 基因2型丙肝RNA 血漿 |
JL-FA-75 | HCV RNA PLASMA Genotype 3 | 基因3型丙肝RNA 血漿 |
JL-FA-76 | HCV RNA PLASMA Genotype 4 | 基因4型丙肝RNA 血漿 |
JL-FA-77 | HCV RNA PLASMA Genotype 5 | 基因5型丙肝RNA 血漿 |
JL-FA-78 | HCV RNA PLASMA Genotype 6 | 基因6型丙肝RNA 血漿 |
JL-FA-79 | HCV Riba single band | 丙肝免疫印跡單波段 |
JL-FA-80 | HCV RIBA Pos. (multiple bands) | 丙肝免疫印跡陽性多波段 |
JL-FA-81 | HCV Negative | 丙肝陰性 |
JL-FA-82 | HCV RNA Pos (quantitative) | 丙肝RNA陽性（定量） |
JL-FA-83 | Hepatitis E | 戊型肝炎 |
JL-FA-84 | Herpes Simplex Virus (HSV)1/2 Positive Plasma | 單純性皰疹病毒1/2陽性血漿 |
JL-FA-85 | Herpes Simplex Virus (HSV) 1 Negative Plasma | 單純性皰疹病毒1 陰性血漿 |
JL-FA-86 | Herpes Simplex Virus (HSV) 1 IgG | 單純性皰疹病毒1 IGG |
JL-FA-87 | Herpes Simplex Virus (HSV 1) IgM | 單純性皰疹病毒1 IGM |
JL-FA-88 | Herpes Simplex Virus (HSV) 2 IgG | 單純性皰疹病毒2 IGG |
JL-FA-89 | Herpes Simplex Virus (HSV) 2 IgM | 單純性皰疹病毒2 IGG |
JL-FA-90 | Histone | 組蛋白 |
JL-FA-91 | Human Anti Mouse Ab (HAMA) | 人抗鼠抗體 |
JL-FA-92 | Human immunodeficiency virus (HIV) 1 Neg | HIV I 陰性 |
JL-FA-93 | anti Human immunodeficiency virus (HIV) 1 Plasma | 抗HIV I 血漿 |
JL-FA-94 | anti Human immunodeficiency virus (HIV) 1 Serum | 抗HIV I 血清 |
JL-FA-95 | anti Human immunodeficiency virus (HIV) 2 Western Blot Tested | 抗HIV 2 免疫印跡 |
JL-FA-96 | anti Human immunodeficiency virus (HIV) 1/2 2 HIV (+) | 抗HIV 1/2 2 HIV陽性 |
JL-FA-97 | Human immunodeficiency virus (HIV) Ag | HIV抗原 |
JL-FA-98 | HIV RNA (quantitative) Plasma | HIV RNA 定量血漿 |
JL-FA-99 | HIV RNA (quantitative) Serum | HIV RNA 定量血清 |
JL-FA-100 | HIV1 Subtype A | HIV1 亞型A |
JL-FA-101 | HIV1 Subtype B | HIV1 亞型B |
JL-FA-102 | HIV1 Subtype C | HIV1 亞型C |
JL-FA-103 | HIV1 Subtype D | HIV1 亞型D |
JL-FA-104 | HIV1 Subtype E | HIV1 亞型E |
JL-FA-105 | HIV1 Subtype F | HIV1 亞型F |
JL-FA-106 | HIV1 Subtype G | HIV1 亞型G |
JL-FA-107 | HIV1 Subtype H | HIV1 亞型H |
JL-FA-108 | HIV1 Subtype J | HIV1 亞型J |
JL-FA-109 | HIV1 Subtype K | HIV1 亞型K |
JL-FA-110 | HIV1 Group O | HIV1 亞型O |
JL-FA-111 | Human immunodeficiency virus (HIV) 2 Antibody Plasma | HIV 2 抗體血漿 |
JL-FA-112 | Human immunodeficiency virus (HIV) 2 Antibody Serum | HIV 2 抗體血清 |
JL-FA-113 | HPV (Human Papiloma Virus) Negative | 人乳狀瘤病毒HPV陰性 |
JL-FA-114 | HPV (Human Papiloma Virus) Positive | 人乳狀瘤病毒HPV陽性 |
JL-FA-115 | Human immunodeficiency virus (HIV) Antibody HCV Antibody Plasma COINFECTED | HIV 抗體 HCV |
JL-FA-116 | Human T-cell Lymphotropic Virus (HTLV) I/II | 人嗜T淋巴細(xì)胞病毒(HTLV) I/II |
JL-FA-117 | Human T-cell Lymphotropic Virus (HTLV) I | 人嗜T淋巴細(xì)胞病毒(HTLV) I |
JL-FA-118 | Human T-cell Lymphotropic Virus (HTLV) II | 人嗜T淋巴細(xì)胞病毒(HTLV) II |
JL-FA-119 | Jo-1 | 多發(fā)性肌炎抗原JO-1 |
JL-FA-120 | IgE < 5,000 Ku/L | IgE < 5,000 Ku/L |
JL-FA-121 | Legionella | 軍團桿菌屬 |
JL-FA-122 | Leptospira | 軍團桿菌屬 |
JL-FA-123 | Lyme Disease | 萊姆(氏)病:蜱傳播的全身性疾病,常在夏季發(fā)生 |
JL-FA-124 | Lyme IgG | 萊姆(氏)病 IGG |
JL-FA-125 | Lyme IgM | 萊姆(氏)病 IGM |
JL-FA-126 | Lyme Disease Neg | 萊姆(氏)病 陰性 |
JL-FA-127 | Malaria | 瘧疾 |
JL-FA-128 | Mononucleosis (infectious) | 單核細(xì)胞增多癥（有傳染性的） |
JL-FA-129 | Mononucleosis Negative | 單核細(xì)胞增多癥陰性 |
JL-FA-130 | Measles Negative | 麻疹 陰性 |
JL-FA-131 | Measles IgG | 麻疹 IGG |
JL-FA-132 | Measles IgM | 麻疹 IGM |
JL-FA-133 | Microsomal Anti-thyroid peroxidase antibody (TPO) Positive Plasma Standard Titer (typically 1,000-3,000 IU/mL) | 微粒體抗甲狀腺過氧化物酶抗體 |
JL-FA-134 | Microsomal Anti-thyroid peroxidase antibody (TPO) Negative Plasma | 微粒體抗甲狀腺過氧化物酶抗體 |
JL-FA-135 | Anti-mitochondrial antibody (AMA) | 抗線粒體抗體 |
JL-FA-136 | Multiple Sclerosis | 多發(fā)性硬化癥 |
JL-FA-137 | Mumps IgG | 流行性腮腺炎 IGG |
JL-FA-138 | Mumps Ab IgM | 流行性腮腺炎抗體 IGM |
JL-FA-139 | Mumps Antibody Negative Plasma | 流行性腮腺炎抗體陰性血漿 |
JL-FA-140 | Mumps Antibody Negative Serum | 流行性腮腺炎抗體陰性血清 |
JL-FA-141 | Myeloma Plasma | 骨髓瘤血漿 |
JL-FA-142 | Myeloma IgA | 骨髓瘤IGA |
JL-FA-143 | Myeloma IgE | 骨髓瘤IGE |
JL-FA-144 | Myeloma IgG | 骨髓瘤IGG |
JL-FA-145 | Myeloma IgM | 骨髓瘤IGM |
JL-FA-146 | Mycoplasma | 支原體 |
JL-FA-147 | Mycoplasma Negative | 支原體陰性 |
JL-FA-148 | Mycoplasma IgG | 支原體IGG |
JL-FA-149 | Mycoplasma IgM | 支原體IGM |
JL-FA-150 | Mycoplasma PCR | 支原體PCR |
JL-FA-151 | Normal Human Plasma | 正常人血漿 |
JL-FA-152 | Normal Human Serum | 正常人血清 |
JL-FA-153 | Nuclear Antibody Centromere | 核抗體著絲粒 |
JL-FA-154 | Nuclear Antibody, Speckled ANA | 核抗體，斑點抗核抗體 |
JL-FA-155 | Nuclear Antibody, Nucleolar ANA | 核抗體,核仁抗核抗體 |
JL-FA-156 | Nuclear Antibody, Homogeneous ANA | 核抗體，同質(zhì)抗核抗體 |
JL-FA-157 | Nuclear Antiobody, Speckled. (ANA) Negative | 核抗體，斑點。抗核抗體陰性 |
JL-FA-158 | P-ANCA (associated neutrophil cytoplasmic antibodies) | 相關(guān)的嗜中性粒細(xì)胞胞漿抗體 |
JL-FA-159 | Parietal Cell Antibody (PCA) | 胃)壁細(xì)胞抗體 |
JL-FA-160 | Parvo positive plasma | 細(xì)小病毒陽性血漿 |
JL-FA-161 | Parvo IgM | 細(xì)小病毒 IGM |
JL-FA-162 | Parvo IgG | 細(xì)小病毒 IGG |
JL-FA-163 | Parvo Negative Plasma | 細(xì)小病毒陰性血漿 |
JL-FA-164 | Parvo DNA positive | 細(xì)小病毒 DNA 陽性 |
JL-FA-165 | Phospholipid Positive Plasma | 磷脂陽性血漿 |
JL-FA-166 | Prothrombin | 凝血酶原,凝血因子 |
JL-FA-167 | Rheumatoid Factor (RF) <1000 IU/mL | 類風(fēng)濕因子<1000 IU/mL |
JL-FA-168 | Rheumatoid Factor (RF) 1001-2000 IU/mL | 類風(fēng)濕因子1001-2000 IU/mL |
JL-FA-169 | Rheumatoid Factor (RF) 2001-4000 IU/mL | 類風(fēng)濕因子 2001-4000 IU/mL |
JL-FA-170 | Rheumatoid Factor (RF) 4001-5000 IU/mL | 類風(fēng)濕因子 4001-5000 IU/mL |
JL-FA-171 | Rheumatoid Factor (RF) >5000 IU/mL | 類風(fēng)濕因子>5000 IU/mL |
JL-FA-172 | Ribonucleoprotein (RNP) Positive | 核糖核蛋白陽性 |
JL-FA-173 | Rubella Chimeric | 風(fēng)疹 |
JL-FA-174 | Rubella Negative | 風(fēng)疹陰性 |
JL-FA-175 | Rubella IgG | 風(fēng)疹I(lǐng)GG |
JL-FA-176 | Rubella IgM | 風(fēng)疹I(lǐng)GM |
JL-FA-177 | Rubeola Negative Plasma | 風(fēng)疹陰性血漿 |
JL-FA-178 | Rubeola IgG | 風(fēng)疹I(lǐng)GG |
JL-FA-179 | Scleroderma (Scl-70) Pos | 膠原沉著病,硬皮病,硬皮癥 陽性 |
JL-FA-180 | Scleroderma (Scl-70) Negative | 硬皮病陰性 |
JL-FA-181 | Sickle Cell Fresh Whole Blood | 鐮刀形紅細(xì)胞新鮮全血 |
JL-FA-182 | Smith (SM) | 抗Smith抗體陽性血清（SLE的特征性抗體） |
JL-FA-183 | SMITH RNP | 抗RNP抗體陽性血清（SLE的特征性抗體） |
JL-FA-184 | Smooth Muscle (ASMA) | 抗平滑肌抗體陽性血清 |
JL-FA-185 | Sjogren syndrome antigen A (SSA) Positive | 舍格倫綜合征或干燥綜合征抗原A 陽性 |
JL-FA-186 | Sjogren syndrome antigen B (SSB) Positive | 舍格倫綜合征抗原B 陽性 |
JL-FA-187 | Sjogren syndrome antigen B (SSB) Negative | 舍格倫綜合征抗原B陰性 |
JL-FA-188 | Streptolysin O Ab (ASO) | 鏈球菌溶血素O抗體 |
JL-FA-189 | Syphilis (RPR - Rapid Plasma Reagin) Positive Plasma | 梅毒（梅毒-快速血漿反應(yīng)）陽性血漿 |
JL-FA-190 | Syphilis (RPR - Rapid Plasma Reagin) Negative Plasma | 梅毒（梅毒-快速血漿反應(yīng)）陰性血漿 |
JL-FA-191 | Syphilis/ATA/T. pallidum IgG | 梅毒ATA/T，蒼白球IGG |
JL-FA-192 | Syphilis/ATA/T. pallidum IgM | 梅毒ATA/T，蒼白球IGM |
JL-FA-193 | Systemic Lupus Erythematosus (SLE) Positive | 全身性紅斑狼瘡陽性 |
JL-FA-194 | Systemic Lupus Erythematosus (SLE) Negative | 全身性紅斑狼瘡陰性 |
JL-FA-195 | TG/TPO Positive (Standard Titer 1,000 - 3000 IU/mL) | 甲狀腺球蛋白/甲狀腺過氧化物酶陽性 |
JL-FA-196 | TG/TPO Negative | 甲狀腺球蛋白/甲狀腺過氧化物酶陰性 |
JL-FA-197 | TTG (Tissue Transglutaminase) | 組織轉(zhuǎn)谷氨酰胺酶 |
JL-FA-198 | TTG (Tissue Transglutaminase) IgA | 組織轉(zhuǎn)谷氨酰胺酶 IGA |
JL-FA-199 | ToRCH (Toxo, Rubella, CMV, HSV) Positive | 優(yōu)生優(yōu)育（弓形蟲，風(fēng)疹，巨細(xì)胞，單胞）陽性 |
JL-FA-200 | ToRCH (Toxo, Rubella, CMV, HSV) Negative | 優(yōu)生優(yōu)育（弓形蟲，風(fēng)疹，巨細(xì)胞，單胞）陰性 |
JL-FA-201 | Toxoplasmosis (Toxo) | 弓形蟲病 |
JL-FA-202 | Toxoplasmosis (Toxo) IgG | 弓形蟲病IGG |
JL-FA-203 | Toxoplasmosis (Toxo) IgM | 弓形蟲病IGM |
JL-FA-204 | Thyroglobulin (TG) Positive Plasma | 甲狀腺球蛋白陽性血漿 |
JL-FA-205 | Thyroglobulin (TG) Negative | 甲狀腺球蛋白陰性 |
JL-FA-206 | Varicella-Zoster Virus (VZV) Negative | 水痘-帶狀皰疹病毒陰性 |
JL-FA-207 | Varicella-Zoster Virus (VZV) IgG | 水痘-帶狀皰疹病毒IGG |
JL-FA-208 | Varicella-Zoster Virus (VZV) IgM | 水痘-帶狀皰疹病毒IGM |
JL-FA-209 | West Nile Virus (WNV) | 西尼羅河腦炎病毒 |
JL-FA-210 | West Nile Virus (WNV) IgM | 西尼羅河腦炎病毒IGM |
美國
RTKs通過光激活二聚化作用調(diào)節(jié)發(fā)育是哺乳動物受體的光激活二聚化作用的*個實例。光控制下的RTK提供了強大的光遺傳學(xué)的方法來啟動細(xì)胞信號和操縱細(xì)胞的行為。新開發(fā)的受體引發(fā)癌癥和血液中內(nèi)皮細(xì)胞復(fù)雜的細(xì)胞活動。這些細(xì)胞代表根據(jù)光控行為的新模型，以及能夠用新的方法來確定藥物。這與癌細(xì)胞的相反，細(xì)胞信號轉(zhuǎn)導(dǎo)的不受控制的活化導(dǎo)致惡性腫瘤有關(guān)的特征，信號轉(zhuǎn)導(dǎo)的光激活可能拯救退行性疾病的細(xì)胞存活和功能。
“漸凍癥”是運動神經(jīng)元病的一種，患者逐漸喪失運動機能甚至癱瘓，其中有名的是英國科學(xué)家霍金。這種病被認(rèn)為與神經(jīng)膠質(zhì)細(xì)胞異常有關(guān)，神經(jīng)膠質(zhì)細(xì)胞可負(fù)責(zé)維持神經(jīng)細(xì)胞的網(wǎng)絡(luò)并向神經(jīng)細(xì)胞提供營養(yǎng)。
京都大學(xué)教授井上治久率領(lǐng)的研究小組，利用ips細(xì)胞制作出可變化為神經(jīng)膠質(zhì)細(xì)胞的前驅(qū)細(xì)胞，然后向24只患有漸凍癥的實驗鼠脊髓各移植了約8萬個這種細(xì)胞。
結(jié)果發(fā)現(xiàn)，移植了前驅(qū)細(xì)胞的24只漸凍癥實驗鼠的平均生存期為162天，而沒有移植的24只實驗鼠僅為150天。研究小組說，移植的前驅(qū)細(xì)胞幾乎全部變?yōu)樯窠?jīng)膠質(zhì)細(xì)胞之一的星形膠質(zhì)細(xì)胞，開始產(chǎn)生維持神經(jīng)細(xì)胞所需的蛋白質(zhì)，而且這些移植的細(xì)胞沒有發(fā)生癌變。
研究小組還說，實驗鼠的10天相當(dāng)于人類的數(shù)個月到半年時間，不過單純換算為天數(shù)比較困難。他們準(zhǔn)備今后將這種前驅(qū)細(xì)胞與利用iPS細(xì)胞制作的運動神經(jīng)細(xì)胞一起移植，以調(diào)查會取得什么樣的效果。
英國布里斯托爾大學(xué)，得克薩斯大學(xué)西南醫(yī)學(xué)中心和梅奧診所的研究人員發(fā)現(xiàn)，一個基因的突變，削弱了細(xì)胞內(nèi)的正常轉(zhuǎn)運蛋白的能力。
這些蛋白質(zhì)的缺乏可能是為什么身體會失去負(fù)責(zé)產(chǎn)生化學(xué)物質(zhì)多巴胺的神經(jīng)細(xì)胞的部分原因。
已知VPS35基因突變與帕金森氏病有關(guān)，但直到現(xiàn)在，專家一直無法查明其作用機制。
發(fā)表于2014年6月26日的《Current biology》雜志上的這項研究表明，VPS35突變削弱細(xì)胞轉(zhuǎn)運貨物蛋白質(zhì)的一個子集到正確目的地的能力。
他們還確定了影響這個突變的三個額外蛋白質(zhì)，其中的一些與帕金森氏病有關(guān)。
布里斯托爾大學(xué)的生物化學(xué)教授彼得·卡倫說：“與VPS35突變相關(guān)的分子缺陷的發(fā)現(xiàn)，為研究這種疾病的病因提供了一個令人興奮的潛在途徑。本研究顯著提供越來越多的證據(jù)表明，VPS35是retromer復(fù)合體中的一部分，是帕金森氏病和其他神經(jīng)退行性疾病的一個潛在治療靶點。”
美國
我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
二維碼掃一掃
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】
RTKs regulate development through photoactivation dimerization as the first instance of photoreactive dimerization of mammalian receptors. RTK under light control provides a powerful method of optogenetics to initiate cellular signaling and manipulate cellular behavior. The newly developed receptors trigger complex cellular activities of cancer and endothelial cells in the blood. These cells represent new models based on photocontrol behavior, as well as being able to identify new drugs in new ways. This is in contrast to cancer cells, where uncontrolled activation of cell signaling leads to malignancy-related features, and photo-activation of signal transduction may rescue the cell survival and function of degenerative diseases.
"Asymptomatic" is a kind of motor neuron disease, patients gradually lose motor function or even paralysis, of which the most famous is the British scientist Hawking. The disease is thought to be associated with abnormalities in glial cells, which can be responsible for maintaining the network of nerve cells and providing nutrients to nerve cells.
A team led by Professor Inoue Ishiguro of Kyoto University made ips cells to make precursor cells that could change into glial cells. Then, about 80,000 of these 24 cells were transplanted into the spinal cord of 24 experimental rats with gradual freezing frost.
The results showed that the average survival time of 24 mice with asherogenic syndrome transplanted with precursor cells was 162 days compared to only 150 days with 24 mice without transplantation. The team said almost all of the transplanted precursor cells became astrocytes, one of the glial cells, and started producing the proteins needed to sustain the nerve cells, and none of the transplanted cells were cancerous.
The team also said that 10 days of experimental mice is equivalent to a few months to six months of human life, but simple conversion to days is more difficult. In the future, they plan to transplant such precursor cells together with motor nerve cells made from iPS cells to investigate what effect they can achieve.
Researchers at the University of Bristol, the University of Texas Southwestern Medical Center and Mayo Clinic have found that a mutation in a gene impairs the ability of normal transporters within the cell.
The lack of these proteins may be part of the reason why the body loses nerve cells responsible for the chemical dopamine production.
Known VPS35 gene mutation and Parkinson's disease, but until now, experts have been unable to identify the mechanism of action.
The study, published in Current Biology, June 26, 2014, shows that VPS35 mutations impair the ability of cells to transport a subset of cargo proteins to the correct destination.
They also identified three additional proteins that affect this mutation, some of which are related to Parkinson's disease.
Peter Karen, a professor of biochemistry at the University of Bristol, said: "The discovery of molecular defects associated with mutations in VPS35 provides an exciting and potential pathway for studying the etiology of this disease." This study significantly provided more and more There is much evidence that VPS35 is part of the retromer complex and is a potential therapeutic target for Parkinson's disease and other neurodegenerative diseases. "
